Weight-loss drugs help people shed weight, protecting them from strokes and heart attacks. But many people gain weight again after stopping taking GLP-1 receptor agonists such as semaglutide (including trade names Ozempic and Wegovy) and tirzepatide (Mounjaro). For type 2 diabetes patients, the risk of serious cardiovascular events and death increases significantly once they stop treatment, according to a study published in The Lancet Regional Health Europe. About 80,000 people with type 2...